Vol 82, No 3 (2011)

open access

Page views 530
Article views/downloads 1349
Get Citation

Connect on Social Media

Connect on Social Media

Influence of estradiol administration mode on plasma insulin-like growth factor-I (IGF-I) and its binding proteins 1 and 3 concentration in postmenopausal women treated with norethisterone acetate

Tomasz Milewicz, Józef Krzysiek, Iwona Rogatko, Krystyna Sztefko, Ewa Stochmal, Alicja Hubalewska-Dydejczyk, Robert Jach, Stanisław Radowicki
Ginekol Pol 2011;82(3).


Abstract Aim: The aim of the present work was to assess the influence of estradiol administration mode on the plasma IGF-I, IGFBP-1, IGFBP-3 levels in postmenopausal women treated with norethisterone acetate. Material and methods: 39 women were enrolled into the study. Group A – 14 women received transdermal 17β-estradiol (Oesclim 50 – Fournier-Solvay) combined with oral norethisterone 2.5mg daily (Primolut-Nor – Schering), Group B – 10 women on oral 2mg 17β-estradiol combined with oral 1 mg daily norethisterone (Kliogest – Novo-Nordisk). Control group (group C) consisted of 15 postmenopausal women who received no treatment. Basic plasma FSH, estradiol and total IGF-I, IGFBP-1 as well as IGFBP-3 levels were measured initially and at the 52nd week of the study. Results: The mean plasma FSH level was reduced and mean plasma estradiol level was increased in groups A and B during hormone therapy. Mean plasma levels of total IGF-I, IGFBP-1, IGFBP-3 as well as IGFBP-3/IGF-I ratio did not changed significantly during 52 weeks of observation in groups A, B and C. The comparison of plasma IGF-I, IGFBP-1, IGFBP-3 between groups at the initial visit and after 52 weeks showed the lowest concentration f IGBP-3 in group B. Other parameters showed no differences among the three groups. Conclusion: Mode of administration of estradiol did not influenced the plasma levels of IGF-I, IGFBP-1, IGFBP-3 in postmenopausal women treated with norethisterone acetate.

Article available in PDF format

View PDF Download PDF file